Cargando…
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Non-alcoholic fatty liver disease (NAFLD) is an ‘umbrella’ term, comprising a spectrum ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and eventually cirrhosis and hepatocellular carcinoma. NAFLD has evolved as a major health problem in recent years. Discovering...
Autores principales: | Androutsakos, Theodoros, Nasiri-Ansari, Narjes, Bakasis, Athanasios-Dimitrios, Kyrou, Ioannis, Efstathopoulos, Efstathios, Randeva, Harpal S., Kassi, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953901/ https://www.ncbi.nlm.nih.gov/pubmed/35328527 http://dx.doi.org/10.3390/ijms23063107 |
Ejemplares similares
-
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2022) -
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
por: Flessa, Christina-Maria, et al.
Publicado: (2022) -
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((-/-)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
por: Nasiri-Ansari, Narjes, et al.
Publicado: (2021) -
Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?
por: Bakasis, Athanasios-Dimitrios, et al.
Publicado: (2021) -
Atherosclerotic and Cardio-Metabolic Diseases: From Molecular Basis to Therapeutic Advances
por: Kassi, Eva, et al.
Publicado: (2023)